Paromomycin

Drug Profile

Paromomycin

Alternative Names: Aminosidine sulfate; Gabbromicina; Paromomycin Intramuscular Injection; Paromomycin sulfate; PMIM

Latest Information Update: 09 Mar 2015

Price : $50

At a glance

  • Originator Institute for OneWorld Health
  • Developer Drugs for Neglected Diseases Initiative Foundation; Institute for OneWorld Health; PATH
  • Class Aminoglycosides; Anthelmintics; Antibacterials; Antiprotozoals; Oligosaccharides; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Visceral leishmaniasis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Visceral leishmaniasis

Most Recent Events

  • 09 Mar 2015 No recent reports on development identified - Registered for Visceral leishmaniasis in Nepal (IM)
  • 15 Oct 2014 Efficacy and adverse events data from a phase III trial in Visceral leishmaniasis released by Drugs for Neglected Diseases Initiative Foundation
  • 17 Dec 2012 Registered for Visceral leishmaniasis in Uganda (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top